Dr. Kelly on Phase Ib Study of Reolysin Plus Bortezomib in Multiple Myeloma

Kevin R. Kelly, MD, PhD
Published: Friday, Feb 10, 2017



Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

This is a phase I clinical trial evaluting an oncolytic virus reolysin in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

The goal is to find the maximum tolerated dose of reolysin. Preliminary results regarding immune system activation are promising.

The study is currently ongoing. Next steps include expanding the study to include more patients to confirm safety.
 


Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine discusses reolysin plus bortezomib (Velcade) in paitents with multiple myeloma.

This is a phase I clinical trial evaluting an oncolytic virus reolysin in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

The goal is to find the maximum tolerated dose of reolysin. Preliminary results regarding immune system activation are promising.

The study is currently ongoing. Next steps include expanding the study to include more patients to confirm safety.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x